This article is more than 5 years old. Information may no longer be current.

STAAR Surgical's Visian TICL, Visian ICH approved for commercial use in China

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MONROVIA, Calif. — STAAR Surgical has received approval from the State Food and Drug Administration of the People's Republic of China to market its Visian Toric Implantable Collamer Lens for treating myopia and astigmatism, according to a press release from the company.

The agency has also approved the STAAR Visian ICH, an implantable collamer lens for correcting hyperopia, the release said.

"The approval of both the Visian Toric ICL and the Visian Hyperopic ICL represents a solid endorsement of the STAAR technology. The Visian Myopic ICL was approved in China during July 2006 and has enjoyed significant growth. With these additional approvals, we are positioned to expand our presence in a market where the demographics are very favorable," said Barry G. Caldwell, president and CEO of STAAR Surgical.

The ICL, TICL and ICH are the only minimally invasive foldable lenses of their kind approved for commercial use in China, according to the release.